In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating and $13.00 price target on Achillion Pharmaceuticals (NASDAQ: ACHN ). BofA Merrill Lynch noted, “In early January, ACHN plans to disclose interim data from an ongoing pilot study evaluating its second generation HCV NS5a inhibitor ACH-3102